Molecular Mechanisms of Ferroptosis in Cardiovascular Disease

Overview

Journal Mol Cell Biochem

Publisher Springer

Specialty Biochemistry

Date 2024 Feb 19

PMID 38374233

Authors

Qun Zeng

Tingting Jiang

Affiliations

Soon will be listed here.

Abstract

Ferroptosis is a newly recognized type of regulated cell death that is characterized by the accumulation of iron and lipid peroxides in cells. Studies have shown that ferroptosis plays a significant role in the pathogenesis of various diseases, including cardiovascular diseases. In cardiovascular disease, ferroptosis is associated with ischemia-reperfusion injury, myocardial infarction, heart failure, and atherosclerosis. The molecular mechanisms underlying ferroptosis include the iron-dependent accumulation of lipid peroxidation products, glutathione depletion, and dysregulation of lipid metabolism, among others. This review aims to summarize the current knowledge of the molecular mechanisms of ferroptosis in cardiovascular disease and discuss the potential therapeutic strategies targeting ferroptosis as a treatment for cardiovascular disease.

Citing Articles

Regulation of cardiac ferroptosis in diabetic human heart failure: uncovering molecular pathways and key targets.

Gawargi F, Mishra P Cell Death Discov. 2024; 10(1):268.

PMID: 38824159 PMC: 11144210. DOI: 10.1038/s41420-024-02044-w.

References

Jiang X, Stockwell B, Conrad M . Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021; 22(4):266-282. PMC: 8142022. DOI: 10.1038/s41580-020-00324-8. View

Liang D, Minikes A, Jiang X . Ferroptosis at the intersection of lipid metabolism and cellular signaling. Mol Cell. 2022; 82(12):2215-2227. PMC: 9233073. DOI: 10.1016/j.molcel.2022.03.022. View

Qiu Y, Cao Y, Cao W, Jia Y, Lu N . The Application of Ferroptosis in Diseases. Pharmacol Res. 2020; 159:104919. DOI: 10.1016/j.phrs.2020.104919. View

Fang X, Ardehali H, Min J, Wang F . The molecular and metabolic landscape of iron and ferroptosis in cardiovascular disease. Nat Rev Cardiol. 2022; 20(1):7-23. PMC: 9252571. DOI: 10.1038/s41569-022-00735-4. View

Guo Y, Lu C, Hu K, Cai C, Wang W . Ferroptosis in Cardiovascular Diseases: Current Status, Challenges, and Future Perspectives. Biomolecules. 2022; 12(3). PMC: 8945958. DOI: 10.3390/biom12030390. View

Yang X, Kawasaki N, Min J, Matsui T, Wang F . Ferroptosis in heart failure. J Mol Cell Cardiol. 2022; 173:141-153. PMC: 11225968. DOI: 10.1016/j.yjmcc.2022.10.004. View

Bai T, Li M, Liu Y, Qiao Z, Wang Z . Inhibition of ferroptosis alleviates atherosclerosis through attenuating lipid peroxidation and endothelial dysfunction in mouse aortic endothelial cell. Free Radic Biol Med. 2020; 160:92-102. DOI: 10.1016/j.freeradbiomed.2020.07.026. View

Zhao W, Zhou Y, Xu T, Wu Q . Ferroptosis: Opportunities and Challenges in Myocardial Ischemia-Reperfusion Injury. Oxid Med Cell Longev. 2021; 2021:9929687. PMC: 8557044. DOI: 10.1155/2021/9929687. View

Li Y, Feng D, Wang Z, Zhao Y, Sun R, Tian D . Ischemia-induced ACSL4 activation contributes to ferroptosis-mediated tissue injury in intestinal ischemia/reperfusion. Cell Death Differ. 2019; 26(11):2284-2299. PMC: 6889315. DOI: 10.1038/s41418-019-0299-4. View

10.

Hong M, Rong J, Tao X, Xu Y . The Emerging Role of Ferroptosis in Cardiovascular Diseases. Front Pharmacol. 2022; 13:822083. PMC: 8826236. DOI: 10.3389/fphar.2022.822083. View

11.

Wu H, Wang F, Ta N, Zhang T, Gao W . The Multifaceted Regulation of Mitochondria in Ferroptosis. Life (Basel). 2021; 11(3). PMC: 8001967. DOI: 10.3390/life11030222. View

12.

Wu S, Mao C, Kondiparthi L, Poyurovsky M, Olszewski K, Gan B . A ferroptosis defense mechanism mediated by glycerol-3-phosphate dehydrogenase 2 in mitochondria. Proc Natl Acad Sci U S A. 2022; 119(26):e2121987119. PMC: 9245637. DOI: 10.1073/pnas.2121987119. View

13.

Jang S, Chapa-Dubocq X, Tyurina Y, St Croix C, Kapralov A, Tyurin V . Elucidating the contribution of mitochondrial glutathione to ferroptosis in cardiomyocytes. Redox Biol. 2021; 45:102021. PMC: 8187237. DOI: 10.1016/j.redox.2021.102021. View

14.

Haarhaus M, Cianciolo G, Barbuto S, La Manna G, Gasperoni L, Tripepi G . Alkaline Phosphatase: An Old Friend as Treatment Target for Cardiovascular and Mineral Bone Disorders in Chronic Kidney Disease. Nutrients. 2022; 14(10). PMC: 9144546. DOI: 10.3390/nu14102124. View

15.

Cardoso A, Lam N, Savla J, Nakada Y, Pereira A, Elnwasany A . Mitochondrial Substrate Utilization Regulates Cardiomyocyte Cell Cycle Progression. Nat Metab. 2020; 2(2):167-178. PMC: 7331943. View

16.

Chan D . Mitochondrial Dynamics and Its Involvement in Disease. Annu Rev Pathol. 2019; 15:235-259. DOI: 10.1146/annurev-pathmechdis-012419-032711. View

17.

Jiao H, Jiang D, Du W, Ji L, Yang Y, Li X . Mitocytosis, a migrasome-mediated mitochondrial quality-control process. Cell. 2021; 184(11):2896-2910.e13. DOI: 10.1016/j.cell.2021.04.027. View

18.

Read A, Bentley R, Archer S, Dunham-Snary K . Mitochondrial iron-sulfur clusters: Structure, function, and an emerging role in vascular biology. Redox Biol. 2021; 47:102164. PMC: 8577454. DOI: 10.1016/j.redox.2021.102164. View

19.

Fang X, Wang H, Han D, Xie E, Yang X, Wei J . Ferroptosis as a target for protection against cardiomyopathy. Proc Natl Acad Sci U S A. 2019; 116(7):2672-2680. PMC: 6377499. DOI: 10.1073/pnas.1821022116. View

20.

Kitakata H, Endo J, Ikura H, Moriyama H, Shirakawa K, Katsumata Y . Therapeutic Targets for DOX-Induced Cardiomyopathy: Role of Apoptosis vs. Ferroptosis. Int J Mol Sci. 2022; 23(3). PMC: 8835899. DOI: 10.3390/ijms23031414. View